ES2187659T3 - Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. - Google Patents
Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.Info
- Publication number
- ES2187659T3 ES2187659T3 ES96921467T ES96921467T ES2187659T3 ES 2187659 T3 ES2187659 T3 ES 2187659T3 ES 96921467 T ES96921467 T ES 96921467T ES 96921467 T ES96921467 T ES 96921467T ES 2187659 T3 ES2187659 T3 ES 2187659T3
- Authority
- ES
- Spain
- Prior art keywords
- amilina
- agonists
- type
- treatment
- mellitus diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
METODOS PARA TRATAR LA DIABETES MELLITUS TIPO II NO DEPENDIENTE DE INSULINA QUE INCLUYEN LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UN AGONISTA DE AMILINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/483,188 US6143718A (en) | 1995-06-07 | 1995-06-07 | Treatment of Type II diabetes mellutis with amylin agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187659T3 true ES2187659T3 (es) | 2003-06-16 |
Family
ID=23919034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96921467T Expired - Lifetime ES2187659T3 (es) | 1995-06-07 | 1996-06-07 | Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. |
Country Status (19)
Country | Link |
---|---|
US (2) | US6143718A (es) |
EP (1) | EP0772451B1 (es) |
JP (1) | JP4009319B2 (es) |
AT (1) | ATE228849T1 (es) |
AU (1) | AU721489B2 (es) |
BG (1) | BG101230A (es) |
CA (1) | CA2196999C (es) |
CZ (1) | CZ289043B6 (es) |
DE (1) | DE69625157T2 (es) |
DK (1) | DK0772451T3 (es) |
ES (1) | ES2187659T3 (es) |
HU (1) | HUP9700368A3 (es) |
IN (1) | IN181672B (es) |
NO (1) | NO970519L (es) |
PT (1) | PT772451E (es) |
RU (1) | RU2166958C2 (es) |
SK (1) | SK18697A3 (es) |
WO (1) | WO1996040220A1 (es) |
ZA (1) | ZA964838B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
CZ69596A3 (en) * | 1993-09-07 | 1997-06-11 | Amylin Pharmaceuticals Inc | Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility |
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
WO1999034822A1 (en) * | 1998-01-09 | 1999-07-15 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6087334A (en) * | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
AU2003235742B2 (en) * | 2002-01-08 | 2008-08-07 | Amylin Pharmaceuticals, Llc | Use of Amylin agonists to modulate triglycerides |
WO2004004665A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
WO2004104018A2 (en) * | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compositions for delivering peptide yy and pyy agonists |
US8501473B2 (en) * | 2003-07-16 | 2013-08-06 | Evotec International Gmbh | Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
US8114958B2 (en) * | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
CA2556923A1 (en) * | 2004-02-20 | 2005-09-09 | Rinat Neuroscience Corp. | Methods of treating obesity or diabetes using nt-4/5 |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
EP1888043A4 (en) * | 2005-03-11 | 2010-07-28 | Endo Pharmaceuticals Solutions | OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
AU2007210862A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist |
JP2009525319A (ja) * | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | trkBアンタゴニストを投与することにより肥満を治療する方法 |
CN101605556A (zh) * | 2006-12-20 | 2009-12-16 | 瑞纳神经科学公司 | 治疗自体免疫疾病的trkb激动剂 |
EA201070609A1 (ru) * | 2007-11-14 | 2010-12-30 | Амилин Фармасьютикалз, Инк. | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств |
JP5622725B2 (ja) * | 2008-06-25 | 2014-11-12 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド.Endo Pharmaceuticals Solutionsinc. | エキセナチド及び他のポリペプチド類の持続的送達 |
AU2009262263B2 (en) * | 2008-06-25 | 2014-08-14 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent |
CA2740685C (en) | 2008-10-17 | 2018-09-11 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
JP2009149684A (ja) * | 2009-03-11 | 2009-07-09 | Amylin Pharmaceut Inc | アミリン作動薬ペプチド用製剤 |
AU2010223329B2 (en) * | 2009-03-12 | 2016-07-21 | Keybioscience Ag | Treatment of diabetes and metabolic syndrome |
US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
ES2887370T3 (es) * | 2014-09-04 | 2021-12-22 | Novo Nordisk As | Nuevo agonista del receptor de amilina y calcitonina |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
US5367052A (en) * | 1987-04-27 | 1994-11-22 | Amylin Pharmaceuticals, Inc. | Amylin peptides |
US5266561A (en) * | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
US5264372A (en) * | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
ATE205854T1 (de) * | 1991-11-19 | 2001-10-15 | Amylin Pharmaceuticals Inc | Peptide als amylin-agonisten und ihre verwendung |
US5376638A (en) * | 1992-09-01 | 1994-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating renin-related disorders with amylin antagonists |
CZ69596A3 (en) * | 1993-09-07 | 1997-06-11 | Amylin Pharmaceuticals Inc | Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility |
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
-
1995
- 1995-06-07 US US08/483,188 patent/US6143718A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 EP EP96921467A patent/EP0772451B1/en not_active Expired - Lifetime
- 1996-06-07 AU AU62685/96A patent/AU721489B2/en not_active Ceased
- 1996-06-07 IN IN1053CA1996 patent/IN181672B/en unknown
- 1996-06-07 PT PT96921467T patent/PT772451E/pt unknown
- 1996-06-07 ZA ZA9604838A patent/ZA964838B/xx unknown
- 1996-06-07 RU RU97104029/14A patent/RU2166958C2/ru not_active IP Right Cessation
- 1996-06-07 DE DE69625157T patent/DE69625157T2/de not_active Expired - Lifetime
- 1996-06-07 SK SK186-97A patent/SK18697A3/sk unknown
- 1996-06-07 CZ CZ1997337A patent/CZ289043B6/cs not_active IP Right Cessation
- 1996-06-07 ES ES96921467T patent/ES2187659T3/es not_active Expired - Lifetime
- 1996-06-07 CA CA2196999A patent/CA2196999C/en not_active Expired - Fee Related
- 1996-06-07 DK DK96921467T patent/DK0772451T3/da active
- 1996-06-07 WO PCT/US1996/009875 patent/WO1996040220A1/en not_active Application Discontinuation
- 1996-06-07 AT AT96921467T patent/ATE228849T1/de active
- 1996-06-07 HU HU9700368A patent/HUP9700368A3/hu unknown
- 1996-06-07 JP JP50206197A patent/JP4009319B2/ja not_active Expired - Fee Related
-
1997
- 1997-02-05 NO NO970519A patent/NO970519L/no unknown
- 1997-02-13 BG BG101230A patent/BG101230A/xx unknown
-
2000
- 2000-11-06 US US09/707,370 patent/US6417164B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69625157D1 (de) | 2003-01-16 |
CA2196999C (en) | 2012-09-04 |
EP0772451A4 (en) | 1998-09-30 |
NO970519D0 (no) | 1997-02-05 |
CZ289043B6 (cs) | 2001-10-17 |
EP0772451A1 (en) | 1997-05-14 |
US6417164B1 (en) | 2002-07-09 |
DK0772451T3 (da) | 2003-01-06 |
BG101230A (en) | 1997-10-31 |
DE69625157T2 (de) | 2003-04-17 |
SK18697A3 (en) | 1998-02-04 |
JP4009319B2 (ja) | 2007-11-14 |
HU9700368D0 (en) | 1997-04-28 |
CZ33797A3 (en) | 1997-07-16 |
JPH10503785A (ja) | 1998-04-07 |
ZA964838B (en) | 1997-02-24 |
EP0772451B1 (en) | 2002-12-04 |
ATE228849T1 (de) | 2002-12-15 |
US6143718A (en) | 2000-11-07 |
HUP9700368A2 (hu) | 1998-06-29 |
AU721489B2 (en) | 2000-07-06 |
PT772451E (pt) | 2003-04-30 |
IN181672B (es) | 1998-08-29 |
RU2166958C2 (ru) | 2001-05-20 |
CA2196999A1 (en) | 1996-12-19 |
HUP9700368A3 (en) | 2001-03-28 |
WO1996040220A1 (en) | 1996-12-19 |
NO970519L (no) | 1997-04-07 |
AU6268596A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187659T3 (es) | Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. | |
EP1159961A3 (en) | Treatment of tumors with compounds having RxR retinoid receptor agonist activity | |
EA199800626A1 (ru) | Применение агониста ppar-гамма для лечения синдрома х | |
ES2166110T3 (es) | Agonistas no alostericos de gabaa para tratar trastornos del sueño. | |
AU1718400A (en) | Method for treating pain | |
ES2112431T3 (es) | Procedimiento para el tratamiento de un trastorno mediado por lfa-1. | |
BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
EA200101089A1 (ru) | Новый способ лечения | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
ES2131122T3 (es) | Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina. | |
BR9810444A (pt) | Tratamento de diabete com rosiglitazona e insulina | |
EA199800866A1 (ru) | Способ снятия боли | |
ES2055314T3 (es) | Tratamiento de disfuncion leucocitaria con gm-csf. | |
ES2038064B1 (es) | Instalacion portatil de vacunacion aviar. | |
EA200000039A1 (ru) | Лечение диабета тиазолидиндионом и сульфонилмочевиной | |
MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
MX9206135A (es) | Metodos | |
AR012638A1 (es) | Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional | |
ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
AR018321A1 (es) | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. | |
AU8159882A (en) | Analgesic potentiation of zomepirac with butorphanol | |
MX9304878A (es) | Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. | |
CO5170459A1 (es) | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos | |
MX9205233A (es) | Uso de il-5 para tratar tumores solidos. | |
ECSP972108A (es) | Metodo de tratamiento |